- Home
- NUVL vs ABVX Comparison
NUVL vs ABVX Comparison
Compare NUVL & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- ABVX
- Stock Information
- Founded
- NUVL 2017
- ABVX 2013
- Country
- NUVL United States
- ABVX France
- Employees
- NUVL 200
- ABVX 69
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- ABVX
- Sector
- NUVL Health Care
- ABVX
- Exchange
- NUVL Nasdaq
- ABVX Nasdaq
- Market Cap
- NUVL 6.0B
- ABVX 6.7B
- IPO Year
- NUVL 2021
- ABVX N/A
- Fundamental
- Price
- NUVL $83.09
- ABVX $86.72
- Analyst Decision
- NUVL Strong Buy
- ABVX Strong Buy
- Analyst Count
- NUVL 9
- ABVX 9
- Target Price
- NUVL $118.89
- ABVX $94.11
- AVG Volume (30 Days)
- NUVL 396.7K
- ABVX 969.2K
- Earning Date
- NUVL 11-11-2025
- ABVX 08-11-2025
- Dividend Yield
- NUVL N/A
- ABVX N/A
- EPS Growth
- NUVL N/A
- ABVX N/A
- EPS
- NUVL N/A
- ABVX N/A
- Revenue
- NUVL N/A
- ABVX $7,073,400.00
- Revenue This Year
- NUVL N/A
- ABVX $4.44
- Revenue Next Year
- NUVL N/A
- ABVX N/A
- P/E Ratio
- NUVL N/A
- ABVX N/A
- Revenue Growth
- NUVL N/A
- ABVX N/A
- 52 Week Low
- NUVL $55.54
- ABVX $4.77
- 52 Week High
- NUVL $106.32
- ABVX $92.91
- Technical
- Relative Strength Index (RSI)
- NUVL 56.32
- ABVX 68.69
- Support Level
- NUVL $81.02
- ABVX $81.90
- Resistance Level
- NUVL $86.34
- ABVX $90.70
- Average True Range (ATR)
- NUVL 3.63
- ABVX 2.75
- MACD
- NUVL 0.28
- ABVX -0.69
- Stochastic Oscillator
- NUVL 66.33
- ABVX 61.24
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.